These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 13912814)

  • 41. Quantitative analysis of branched-chain alpha-keto acids as their trimethylsilylated oximes.
    Lancaster G; Lamm P; Scriver CR; Tjoa SS; Mamer OA
    Clin Chim Acta; 1973 Oct; 48(3):279-85. PubMed ID: 4765708
    [No Abstract]   [Full Text] [Related]  

  • 42. ["Atypical" metabolic forms of phenylketonuria (PKU) and leucinosis detected in newborn infants].
    Tănase I; Ciortoloman H; Popescu M; Grigorescu G; Ankăr V
    Physiologie; 1977; 14(4):257-61. PubMed ID: 413127
    [No Abstract]   [Full Text] [Related]  

  • 43. Amino acids levels and lipid peroxidation in maple syrup urine disease patients.
    Barschak AG; Sitta A; Deon M; Busanello EN; Coelho DM; Cipriani F; Dutra-Filho CS; Giugliani R; Wajner M; Vargas CR
    Clin Biochem; 2009 Apr; 42(6):462-6. PubMed ID: 19121297
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Classical maple syrup urine disease: cofactor resistance.
    Elsas LJ; Pask BA; Wheeler FB; Perl DP; Truster S
    Metabolism; 1972 Oct; 21(10):929-44. PubMed ID: 4342010
    [No Abstract]   [Full Text] [Related]  

  • 45. Intermittent maple syrup urine disease: two case reports.
    Axler O; Holmquist P
    Pediatrics; 2014 Feb; 133(2):e458-60. PubMed ID: 24394677
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Maple syrup urine disease variant form: presentation with psychomotor retardation and CT scan abnormalities.
    Verdu A; Lopez-Herce J; Pascual-Castroviejo I; Martinez-Bermejo A; Ugarte M; Garcia MJ
    Acta Paediatr Scand; 1985 Sep; 74(5):815-8. PubMed ID: 4050430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chloride-dependent inhibition of vesicular glutamate uptake by alpha-keto acids accumulated in maple syrup urine disease.
    Reis M; Farage M; Wolosker H
    Biochim Biophys Acta; 2000 Jul; 1475(2):114-8. PubMed ID: 10832024
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maple syrup urine disease.
    LANE MR
    J Pediatr; 1961 Jan; 58():80-5. PubMed ID: 13758724
    [No Abstract]   [Full Text] [Related]  

  • 49. Maple syrup urine disease.
    PATRICK AD
    Arch Dis Child; 1961 Jun; 36(187):269-72. PubMed ID: 13733337
    [No Abstract]   [Full Text] [Related]  

  • 50. Branched chain ketoaciduria (maple syrup urine disease).
    Snyderman SE
    Clin Perinatol; 1976 Mar; 3(1):41-52. PubMed ID: 954344
    [No Abstract]   [Full Text] [Related]  

  • 51. Reduction of plasma concentrations of large neutral amino acids in patients with maple syrup urine disease during crises.
    Wajner M; Vargas CR
    Arch Dis Child; 1999 Jun; 80(6):579. PubMed ID: 10523253
    [No Abstract]   [Full Text] [Related]  

  • 52. Studies in maple syrup urine disease.
    DENT CE; WESTALL RG
    Arch Dis Child; 1961 Jun; 36(187):259-68. PubMed ID: 13721928
    [No Abstract]   [Full Text] [Related]  

  • 53. Intermediate maple syrup urine disease: neuroimaging observations in 3 patients from South India.
    Bindu PS; Shehanaz KE; Christopher R; Pal PK; Ravishankar S
    J Child Neurol; 2007 Jul; 22(7):911-3. PubMed ID: 17715290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A rapid method for assay of branched-chain keto acid decarboxylation in cultured cells and its application to prenatal diagnosis of maple syrup urine disease.
    Fensom AH; Benson PF; Baker JE
    Clin Chim Acta; 1978 Jul; 87(1):169-74. PubMed ID: 668138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Morphological alterations and induction of oxidative stress in glial cells caused by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.
    Funchal C; Latini A; Jacques-Silva MC; Dos Santos AQ; Buzin L; Gottfried C; Wajner M; Pessoa-Pureur R
    Neurochem Int; 2006 Dec; 49(7):640-50. PubMed ID: 16822590
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Branched-chain alpha-keto acids for the diagnosis of maple-syrup-urine disease.
    Parsons H; Fung E; Snyder FF
    N Engl J Med; 1987 Apr; 316(15):951. PubMed ID: 3821846
    [No Abstract]   [Full Text] [Related]  

  • 57. Determination of (S)- and (R)-2-oxo-3-methylvaleric acid in plasma of patients with maple syrup urine disease.
    Wendel U; Even G; Langenbeck U; Schadewaldt P; Hummel W
    Clin Chim Acta; 1992 Jun; 208(1-2):85-91. PubMed ID: 1638756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Definition of the mutation responsible for maple syrup urine disease in Poll Shorthorns and genotyping Poll Shorthorns and Poll Herefords for maple syrup urine disease alleles.
    Dennis JA; Healy PJ
    Res Vet Sci; 1999 Aug; 67(1):1-6. PubMed ID: 10425233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Maple syrup disease and other disorders of keto acid metabolism.
    MENKES JH
    Res Publ Assoc Res Nerv Ment Dis; 1962; 40():69-93. PubMed ID: 13934868
    [No Abstract]   [Full Text] [Related]  

  • 60. Dietary treatment of maple sirup urine disease (branched-chain ketoaciduria).
    Noel MB; Stanley PB; Girz JC; Allen RJ
    J Am Diet Assoc; 1976 Jul; 69(1):62-8. PubMed ID: 932376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.